Michael A. Gold
Expertise in
28
conditions

Dr. Michael A. Gold

Gynecologic Oncology | Oncology
Oklahoma Cancer Specialists And Research Institute, LLC
12697 E 51st St, 
Tulsa, OK 
38 Years of Experience
Expertise in
28
conditions
Oklahoma Cancer Specialists And Research Institute, LLC
12697 E 51st St, 
Tulsa, OK 

Overview

Michael Gold is a Gynecologic Oncologist and an Oncologist in Tulsa, Oklahoma. Dr. Gold has been practicing medicine for over 38 years is highly rated in 28 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Cervical Cancer, Vulvar Cancer, Lymphadenectomy, and Bladder Reconstruction.

His clinical research consists of co-authoring 47 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Jefferson Medical College Of Thomas Jefferson University, 1988

Residency

Thomas Jefferson University Hospital, Inc.

Specialties

Gynecologic Oncology
Oncology

Licenses

Obstetrics & Gynecology in OK

Fellowships

University of Oklahoma College of Medicine - 1996

Hospital Affiliations

Hillcrest Medical Center
Ascension St John Medical Center
Saint Francis Hospital, Inc

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
CommunityCare
  • HMO
GlobalHealth
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

OKLAHOMA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
12697 E 51st St, Tulsa, OK 74146
Other Locations
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA OU PHYSICIANS TULSA
1111 S St Louis Ave, Tulsa, OK 74120
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA OU PHYSICIANS TULSA
4444 E 41st St, Tulsa, OK 74135

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Dostarlimab, Carboplatin, Paclitaxel, Niraparib
Study Phase: Phase 3
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Enrollment Status: Terminated
Publish Date: March 24, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 2, Multicenter, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects With Recurrent or Metastatic Cervical Cancer
A Phase 2, Multicenter, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects With Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: February 28, 2025
Intervention Type: Biological
Study Drug: AK104
Study Phase: Phase 2
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: AGEN-2034 PD-1 Antibody, AGEN-1884 CTLA4 Antibody
Study Phase: Phase 2
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Enrollment Status: Unknown
Publish Date: December 13, 2023
Intervention Type: Drug
Study Drugs: Abemaciclib, Letrozole
Study Phase: Phase 2
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: July 25, 2023
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drug: Prexasertib
Study Phase: Phase 2
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Enrollment Status: Terminated
Publish Date: June 07, 2022
Intervention Type: Drug
Study Phase: Phase 2
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 10 Less Clinical Trials

47 Total Publications

Updated Review for Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection.
Updated Review for Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection.
Journal: Journal of lower genital tract disease
Published: January 13, 2025
Similar Doctors
Katherine M. Moxley
Expertise in
17
conditions
Dr. Katherine M. Moxley
Gynecologic Oncology | Obstetrics and Gynecology | Orthopedics
Expertise in
17
conditions
Dr. Katherine M. Moxley
Gynecologic Oncology | Obstetrics and Gynecology | Orthopedics

Oklahoma State University

2345 Southwest Blvd, 
Tulsa, OK 
 (10.0 miles away)
918-561-5701
Experience:
26+ years
Languages Spoken:
English
See accepted insurances

Katherine Moxley is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Tulsa, Oklahoma. Dr. Moxley has been practicing medicine for over 26 years is highly rated in 17 conditions, according to our data. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Vulvar Cancer, Hysterectomy, and Gastrostomy.

Daron G. Street
Expertise in
13
conditions
Dr. Daron G. Street
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
13
conditions
Dr. Daron G. Street
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Oklahoma Cancer Specialists And Research Institute, LLC

12697 E 51st St, 
Tulsa, OK 
 (0.1 miles away)
918-505-3200
Experience:
40+ years
Languages Spoken:
English
See accepted insurances

Daron Street is a Gynecologic Oncologist and an Oncologist in Tulsa, Oklahoma. Dr. Street has been practicing medicine for over 40 years is highly rated in 13 conditions, according to our data. His top areas of expertise are Malignant Mixed Mullerian Tumor, Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, Hernia Surgery, and Oophorectomy.

Alfred D. Jenkins
Expertise in
15
conditions
Dr. Alfred D. Jenkins
Gynecologic Oncology | Oncology | Surgical Oncology
Expertise in
15
conditions
Dr. Alfred D. Jenkins
Gynecologic Oncology | Oncology | Surgical Oncology

Oklahoma Cancer Specialists And Research Institute, LLC

12697 E 51st St, 
Tulsa, OK 
 (0.1 miles away)
918-505-3200
Experience:
33+ years
Languages Spoken:
English
See accepted insurances

Alfred Jenkins is a Gynecologic Oncologist and an Oncologist in Tulsa, Oklahoma. Dr. Jenkins has been practicing medicine for over 33 years is highly rated in 15 conditions, according to our data. His top areas of expertise are Vulvar Cancer, Lump in the Abdomen, Malignant Mixed Mullerian Tumor, Oophorectomy, and Salpingo-Oophorectomy.

Frequently Asked Questions about Dr. Michael A. Gold

How do I make an appointment with Dr. Michael A. Gold?

You can book an appointment with Dr. Michael A. Gold by calling their office at 918-505-3200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael A. Gold a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael A. Gold is classified as an Elite expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael A. Gold specialize in?

While Dr. Michael A. Gold is a Gynecologic Oncology, they have specific expertise in Endometrial Cancer, Cervical Cancer, and Vulvar Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gynecologic Oncology.

Does Dr. Michael A. Gold participate in research or clinical trials?

Yes. Dr. Michael A. Gold has published 47 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Michael A. Gold's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael A. Gold accept my insurance?

Dr. Michael A. Gold accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 918-505-3200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gold's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 15 Advanced Conditions
View All 66 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile